| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetes Mellitus, Type 2 | 93 | 2022 | 148 | 21.870 |
Why?
|
| Diabetes Mellitus | 73 | 2022 | 114 | 12.610 |
Why?
|
| Insulin | 77 | 2022 | 109 | 10.220 |
Why?
|
| Hypoglycemic Agents | 55 | 2022 | 83 | 9.960 |
Why?
|
| Humans | 200 | 2022 | 2493 | 7.670 |
Why?
|
| Glycated Hemoglobin A | 45 | 2019 | 64 | 6.570 |
Why?
|
| Blood Glucose | 82 | 2020 | 110 | 6.520 |
Why?
|
| Prediabetic State | 9 | 2021 | 16 | 4.140 |
Why?
|
| Diabetes Mellitus, Type 1 | 25 | 2019 | 31 | 4.010 |
Why?
|
| Thiazolidinediones | 11 | 2020 | 22 | 3.830 |
Why?
|
| Male | 84 | 2020 | 1649 | 3.230 |
Why?
|
| Blood Glucose Self-Monitoring | 11 | 2019 | 12 | 2.860 |
Why?
|
| Female | 71 | 2020 | 1733 | 2.800 |
Why?
|
| Adult | 53 | 2022 | 807 | 2.720 |
Why?
|
| Middle Aged | 55 | 2020 | 799 | 2.660 |
Why?
|
| Metformin | 8 | 2020 | 13 | 2.660 |
Why?
|
| Glucose Tolerance Test | 27 | 2012 | 36 | 2.450 |
Why?
|
| Cardiovascular Diseases | 6 | 2020 | 36 | 2.300 |
Why?
|
| Insulin Resistance | 17 | 2013 | 44 | 2.250 |
Why?
|
| Research Support as Topic | 10 | 2004 | 14 | 2.120 |
Why?
|
| Diabetic Retinopathy | 11 | 2016 | 45 | 1.860 |
Why?
|
| Primary Health Care | 5 | 2017 | 44 | 1.820 |
Why?
|
| Life Style | 8 | 2022 | 29 | 1.810 |
Why?
|
| Aged | 36 | 2019 | 607 | 1.770 |
Why?
|
| African Americans | 10 | 2016 | 272 | 1.730 |
Why?
|
| Sulfonylurea Compounds | 12 | 2019 | 16 | 1.650 |
Why?
|
| Insulin, Regular, Human | 2 | 2022 | 2 | 1.630 |
Why?
|
| Vitamin D | 4 | 2021 | 21 | 1.600 |
Why?
|
| Patient Education as Topic | 9 | 2017 | 31 | 1.590 |
Why?
|
| United States | 31 | 2014 | 324 | 1.530 |
Why?
|
| Algorithms | 14 | 2012 | 33 | 1.440 |
Why?
|
| Diabetes Complications | 11 | 2009 | 24 | 1.420 |
Why?
|
| Glucose | 25 | 2017 | 39 | 1.330 |
Why?
|
| Societies, Medical | 13 | 2014 | 21 | 1.310 |
Why?
|
| Quality of Life | 6 | 2014 | 60 | 1.310 |
Why?
|
| Obesity | 17 | 2022 | 102 | 1.260 |
Why?
|
| Fasting | 22 | 2020 | 26 | 1.240 |
Why?
|
| Urinary Bladder Neoplasms | 2 | 2017 | 4 | 1.220 |
Why?
|
| Hyperglycemia | 11 | 2012 | 20 | 1.180 |
Why?
|
| Biomarkers | 5 | 2019 | 58 | 1.130 |
Why?
|
| Risk Factors | 14 | 2020 | 240 | 1.120 |
Why?
|
| Minority Groups | 4 | 2007 | 40 | 1.060 |
Why?
|
| Voluntary Health Agencies | 6 | 2001 | 6 | 0.990 |
Why?
|
| Disease Management | 5 | 2014 | 10 | 0.860 |
Why?
|
| Reproducibility of Results | 15 | 2010 | 52 | 0.840 |
Why?
|
| Albuminuria | 3 | 2011 | 20 | 0.840 |
Why?
|
| Self Care | 8 | 2017 | 16 | 0.830 |
Why?
|
| Insulin Infusion Systems | 8 | 2017 | 8 | 0.790 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2020 | 14 | 0.770 |
Why?
|
| Hypertension | 4 | 2014 | 56 | 0.760 |
Why?
|
| Dipeptidyl-Peptidase IV Inhibitors | 1 | 2019 | 1 | 0.750 |
Why?
|
| Urinary Tract Infections | 1 | 2019 | 4 | 0.750 |
Why?
|
| Randomized Controlled Trials as Topic | 8 | 2014 | 24 | 0.740 |
Why?
|
| Hydroxychloroquine | 1 | 2019 | 5 | 0.730 |
Why?
|
| Glyburide | 4 | 2007 | 5 | 0.680 |
Why?
|
| Drug Therapy, Combination | 10 | 2019 | 30 | 0.660 |
Why?
|
| Cholesterol, LDL | 6 | 2017 | 12 | 0.660 |
Why?
|
| Clinical Protocols | 2 | 2017 | 7 | 0.650 |
Why?
|
| Cost-Benefit Analysis | 8 | 2020 | 17 | 0.650 |
Why?
|
| Glucose Intolerance | 4 | 2009 | 5 | 0.630 |
Why?
|
| Pharmacists | 3 | 2009 | 4 | 0.620 |
Why?
|
| Non-alcoholic Fatty Liver Disease | 1 | 2017 | 24 | 0.620 |
Why?
|
| Blood Pressure | 6 | 2017 | 45 | 0.580 |
Why?
|
| Delivery of Health Care | 3 | 2009 | 39 | 0.570 |
Why?
|
| Research Design | 3 | 2014 | 17 | 0.560 |
Why?
|
| Health Maintenance Organizations | 5 | 1999 | 5 | 0.550 |
Why?
|
| Treatment Outcome | 9 | 2011 | 119 | 0.540 |
Why?
|
| Metabolic Syndrome | 2 | 2006 | 23 | 0.530 |
Why?
|
| Reminder Systems | 2 | 2005 | 5 | 0.530 |
Why?
|
| Dyslipidemias | 1 | 2014 | 6 | 0.510 |
Why?
|
| Vitamin D Deficiency | 1 | 2014 | 8 | 0.510 |
Why?
|
| Diabetes, Gestational | 2 | 2020 | 10 | 0.510 |
Why?
|
| Glucose Clamp Technique | 3 | 2013 | 3 | 0.500 |
Why?
|
| Health Transition | 1 | 2014 | 2 | 0.500 |
Why?
|
| Sertraline | 2 | 2011 | 3 | 0.500 |
Why?
|
| Antidepressive Agents | 2 | 2011 | 5 | 0.500 |
Why?
|
| Follow-Up Studies | 5 | 2020 | 95 | 0.490 |
Why?
|
| Prevalence | 5 | 2017 | 114 | 0.490 |
Why?
|
| Inflammation | 1 | 2014 | 44 | 0.490 |
Why?
|
| Muscles | 9 | 1996 | 17 | 0.490 |
Why?
|
| Outsourced Services | 2 | 2004 | 2 | 0.490 |
Why?
|
| Managed Care Programs | 2 | 2007 | 6 | 0.470 |
Why?
|
| Cohort Studies | 3 | 2019 | 56 | 0.470 |
Why?
|
| Triglycerides | 6 | 2008 | 36 | 0.460 |
Why?
|
| Nursing Care | 2 | 2010 | 2 | 0.460 |
Why?
|
| Community Health Centers | 3 | 2005 | 7 | 0.450 |
Why?
|
| Drug Administration Schedule | 7 | 2014 | 24 | 0.440 |
Why?
|
| Hospitalization | 3 | 2008 | 40 | 0.430 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2011 | 2 | 0.430 |
Why?
|
| Postprandial Period | 2 | 2010 | 2 | 0.430 |
Why?
|
| Reagent Strips | 2 | 2004 | 3 | 0.430 |
Why?
|
| Dose-Response Relationship, Drug | 8 | 2014 | 118 | 0.420 |
Why?
|
| Triazoles | 1 | 2011 | 4 | 0.420 |
Why?
|
| Pyrazines | 1 | 2011 | 16 | 0.420 |
Why?
|
| Young Adult | 4 | 2014 | 175 | 0.410 |
Why?
|
| Depressive Disorder | 1 | 2011 | 23 | 0.400 |
Why?
|
| Muscle Proteins | 3 | 1996 | 15 | 0.390 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2010 | 5 | 0.390 |
Why?
|
| Weight Loss | 3 | 2022 | 17 | 0.390 |
Why?
|
| Liver | 7 | 1993 | 120 | 0.380 |
Why?
|
| Research | 2 | 2001 | 18 | 0.380 |
Why?
|
| Carbon Isotopes | 3 | 2009 | 3 | 0.380 |
Why?
|
| Injections | 3 | 2019 | 11 | 0.360 |
Why?
|
| Breath Tests | 1 | 2009 | 1 | 0.360 |
Why?
|
| Time Factors | 8 | 2019 | 120 | 0.350 |
Why?
|
| Needles | 1 | 2008 | 2 | 0.340 |
Why?
|
| Depression | 1 | 2009 | 74 | 0.340 |
Why?
|
| Hypertriglyceridemia | 1 | 2008 | 3 | 0.340 |
Why?
|
| Insulin, Isophane | 2 | 2004 | 3 | 0.330 |
Why?
|
| Diabetic Angiopathies | 4 | 2020 | 6 | 0.330 |
Why?
|
| Cholecalciferol | 2 | 2021 | 7 | 0.330 |
Why?
|
| Quality Assurance, Health Care | 4 | 2007 | 13 | 0.330 |
Why?
|
| Thyrotropin | 1 | 2008 | 6 | 0.330 |
Why?
|
| Insulin, Long-Acting | 3 | 2020 | 4 | 0.320 |
Why?
|
| Diabetic Nephropathies | 4 | 2009 | 10 | 0.320 |
Why?
|
| Mass Screening | 4 | 2014 | 66 | 0.310 |
Why?
|
| Enteral Nutrition | 4 | 1996 | 6 | 0.310 |
Why?
|
| Diabetes Mellitus, Experimental | 5 | 1994 | 22 | 0.300 |
Why?
|
| Medicare | 3 | 2005 | 19 | 0.300 |
Why?
|
| Rats | 17 | 2001 | 432 | 0.290 |
Why?
|
| Treatment Failure | 2 | 2019 | 11 | 0.290 |
Why?
|
| Monosaccharide Transport Proteins | 3 | 1996 | 8 | 0.290 |
Why?
|
| Islam | 1 | 2006 | 5 | 0.290 |
Why?
|
| Medication Adherence | 2 | 2017 | 13 | 0.280 |
Why?
|
| Peptides | 2 | 2005 | 5 | 0.280 |
Why?
|
| Double-Blind Method | 4 | 2012 | 48 | 0.280 |
Why?
|
| California | 7 | 2007 | 93 | 0.280 |
Why?
|
| Venoms | 1 | 2005 | 1 | 0.280 |
Why?
|
| Animals | 22 | 2001 | 1238 | 0.280 |
Why?
|
| Drug Costs | 2 | 2020 | 4 | 0.280 |
Why?
|
| Aged, 80 and over | 3 | 2014 | 246 | 0.270 |
Why?
|
| Dietary Supplements | 3 | 2014 | 13 | 0.270 |
Why?
|
| Hemoglobins, Abnormal | 1 | 2005 | 2 | 0.270 |
Why?
|
| Pregnancy | 4 | 2020 | 305 | 0.260 |
Why?
|
| Muscle, Skeletal | 2 | 1996 | 87 | 0.260 |
Why?
|
| Retrospective Studies | 5 | 2008 | 210 | 0.260 |
Why?
|
| Medicine, Ayurvedic | 1 | 2004 | 3 | 0.260 |
Why?
|
| Phytotherapy | 1 | 2004 | 4 | 0.260 |
Why?
|
| Inpatients | 1 | 2004 | 4 | 0.260 |
Why?
|
| Costs and Cost Analysis | 2 | 2020 | 8 | 0.260 |
Why?
|
| Gait Disorders, Neurologic | 1 | 2004 | 2 | 0.250 |
Why?
|
| Adolescent | 7 | 2011 | 305 | 0.250 |
Why?
|
| Arteriosclerosis | 1 | 2004 | 18 | 0.250 |
Why?
|
| Practice Guidelines as Topic | 4 | 2007 | 35 | 0.250 |
Why?
|
| Peer Review, Research | 1 | 2003 | 1 | 0.240 |
Why?
|
| Periodicals as Topic | 2 | 2002 | 4 | 0.240 |
Why?
|
| Specialties, Nursing | 1 | 2003 | 1 | 0.240 |
Why?
|
| Vitamins | 2 | 2021 | 5 | 0.240 |
Why?
|
| Fatty Acids, Nonesterified | 8 | 1996 | 22 | 0.230 |
Why?
|
| Proteinuria | 2 | 2002 | 4 | 0.230 |
Why?
|
| Europe | 6 | 2014 | 6 | 0.230 |
Why?
|
| Enalapril | 1 | 2002 | 1 | 0.230 |
Why?
|
| Body Weight | 5 | 2009 | 65 | 0.230 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2002 | 5 | 0.230 |
Why?
|
| Risk | 3 | 2017 | 19 | 0.230 |
Why?
|
| Gastric Inhibitory Polypeptide | 1 | 2022 | 1 | 0.230 |
Why?
|
| Growth Hormone | 7 | 1990 | 16 | 0.230 |
Why?
|
| Prospective Studies | 4 | 2019 | 121 | 0.220 |
Why?
|
| Community Health Services | 3 | 2014 | 22 | 0.220 |
Why?
|
| Lipids | 4 | 2014 | 20 | 0.220 |
Why?
|
| Insulin-Like Growth Factor I | 2 | 2014 | 21 | 0.220 |
Why?
|
| Placebos | 2 | 2014 | 9 | 0.220 |
Why?
|
| Body Mass Index | 2 | 2014 | 46 | 0.220 |
Why?
|
| Sex Factors | 2 | 2014 | 75 | 0.210 |
Why?
|
| Reference Values | 5 | 2003 | 42 | 0.210 |
Why?
|
| Diet, Diabetic | 6 | 2007 | 6 | 0.210 |
Why?
|
| Hyperlipidemias | 2 | 1998 | 6 | 0.200 |
Why?
|
| Sensitivity and Specificity | 5 | 2008 | 45 | 0.200 |
Why?
|
| Nutrition Surveys | 2 | 2014 | 40 | 0.200 |
Why?
|
| Disease Progression | 1 | 2020 | 50 | 0.190 |
Why?
|
| Database Management Systems | 1 | 2000 | 12 | 0.190 |
Why?
|
| Family Characteristics | 1 | 2020 | 3 | 0.190 |
Why?
|
| Biological Transport | 7 | 1996 | 13 | 0.190 |
Why?
|
| Glucagon-Like Peptide 1 | 1 | 2019 | 4 | 0.190 |
Why?
|
| Creatinine | 2 | 1999 | 10 | 0.190 |
Why?
|
| Antimalarials | 1 | 2019 | 3 | 0.180 |
Why?
|
| Dietary Carbohydrates | 6 | 2006 | 6 | 0.180 |
Why?
|
| Pilot Projects | 1 | 2019 | 28 | 0.180 |
Why?
|
| Surveys and Questionnaires | 2 | 2010 | 97 | 0.180 |
Why?
|
| Insurance Benefits | 1 | 1999 | 1 | 0.180 |
Why?
|
| Predictive Value of Tests | 3 | 2009 | 32 | 0.180 |
Why?
|
| Regression Analysis | 3 | 2010 | 42 | 0.180 |
Why?
|
| Insulin Glargine | 1 | 2019 | 2 | 0.180 |
Why?
|
| C-Peptide | 7 | 2009 | 7 | 0.180 |
Why?
|
| Case Management | 1 | 1999 | 4 | 0.180 |
Why?
|
| Insulin, Short-Acting | 1 | 2019 | 1 | 0.180 |
Why?
|
| Prognosis | 1 | 2019 | 47 | 0.180 |
Why?
|
| Patient Satisfaction | 2 | 2014 | 16 | 0.170 |
Why?
|
| Dietary Fats | 3 | 1993 | 18 | 0.170 |
Why?
|
| Quality of Health Care | 1 | 1998 | 10 | 0.170 |
Why?
|
| Carbohydrate Metabolism | 5 | 1990 | 8 | 0.160 |
Why?
|
| Injections, Subcutaneous | 2 | 2017 | 8 | 0.160 |
Why?
|
| Dietary Proteins | 2 | 1993 | 2 | 0.160 |
Why?
|
| Diet | 2 | 1993 | 40 | 0.150 |
Why?
|
| Insulins | 1 | 2017 | 1 | 0.150 |
Why?
|
| Receptor, Insulin | 5 | 1991 | 6 | 0.150 |
Why?
|
| Hyperinsulinism | 3 | 2001 | 6 | 0.150 |
Why?
|
| Overweight | 1 | 2016 | 6 | 0.150 |
Why?
|
| Homeostasis | 4 | 2014 | 18 | 0.150 |
Why?
|
| Dietary Fiber | 1 | 1996 | 1 | 0.150 |
Why?
|
| Galactans | 1 | 1996 | 1 | 0.150 |
Why?
|
| Mannans | 1 | 1996 | 1 | 0.150 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 1996 | 26 | 0.150 |
Why?
|
| History, 20th Century | 1 | 2016 | 3 | 0.150 |
Why?
|
| Los Angeles | 4 | 2005 | 210 | 0.150 |
Why?
|
| Adipocytes | 1 | 1996 | 26 | 0.150 |
Why?
|
| Outpatients | 1 | 1996 | 1 | 0.150 |
Why?
|
| Drug Industry | 1 | 2016 | 1 | 0.140 |
Why?
|
| Dexamethasone | 1 | 1996 | 27 | 0.140 |
Why?
|
| Glucocorticoids | 1 | 1996 | 39 | 0.140 |
Why?
|
| Insulin Antagonists | 4 | 1987 | 4 | 0.140 |
Why?
|
| Food, Formulated | 2 | 1992 | 2 | 0.130 |
Why?
|
| Postoperative Complications | 2 | 1994 | 42 | 0.130 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 1 | 2014 | 8 | 0.130 |
Why?
|
| Aorta, Abdominal | 1 | 1994 | 1 | 0.130 |
Why?
|
| Aortic Aneurysm, Abdominal | 1 | 1994 | 2 | 0.130 |
Why?
|
| Interleukin-6 | 1 | 2014 | 21 | 0.130 |
Why?
|
| Arterial Occlusive Diseases | 1 | 1994 | 2 | 0.130 |
Why?
|
| Tissue Distribution | 1 | 2014 | 24 | 0.130 |
Why?
|
| C-Reactive Protein | 1 | 2014 | 17 | 0.130 |
Why?
|
| Benzothiadiazines | 1 | 1994 | 1 | 0.130 |
Why?
|
| Sodium Chloride Symporter Inhibitors | 1 | 1994 | 1 | 0.130 |
Why?
|
| Medical History Taking | 1 | 2014 | 4 | 0.130 |
Why?
|
| Behavior Therapy | 1 | 2014 | 5 | 0.120 |
Why?
|
| Health Status | 1 | 2014 | 39 | 0.120 |
Why?
|
| Waist Circumference | 1 | 2014 | 2 | 0.120 |
Why?
|
| Socioeconomic Factors | 1 | 2014 | 116 | 0.120 |
Why?
|
| Lipid Metabolism | 6 | 1994 | 24 | 0.120 |
Why?
|
| Hypolipidemic Agents | 2 | 2008 | 3 | 0.120 |
Why?
|
| Adipose Tissue | 7 | 1994 | 42 | 0.120 |
Why?
|
| Meta-Analysis as Topic | 2 | 2009 | 2 | 0.120 |
Why?
|
| Carbon Dioxide | 4 | 2009 | 12 | 0.110 |
Why?
|
| Ambulatory Care | 1 | 1992 | 4 | 0.110 |
Why?
|
| Administration, Oral | 3 | 2008 | 19 | 0.110 |
Why?
|
| Age Factors | 2 | 2010 | 90 | 0.110 |
Why?
|
| Rats, Inbred Strains | 6 | 1991 | 38 | 0.110 |
Why?
|
| Protein Kinase C | 1 | 1991 | 5 | 0.110 |
Why?
|
| Serum Albumin | 3 | 1987 | 11 | 0.110 |
Why?
|
| Patient Care Planning | 2 | 2006 | 3 | 0.110 |
Why?
|
| Patient Compliance | 3 | 2005 | 21 | 0.110 |
Why?
|
| Sitagliptin Phosphate | 1 | 2011 | 3 | 0.110 |
Why?
|
| Vanadates | 1 | 1991 | 1 | 0.100 |
Why?
|
| Physicians, Primary Care | 1 | 2011 | 1 | 0.100 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 1991 | 4 | 0.100 |
Why?
|
| Myocardial Infarction | 2 | 2005 | 14 | 0.100 |
Why?
|
| Rats, Sprague-Dawley | 4 | 1996 | 179 | 0.100 |
Why?
|
| Glucose Transporter Type 4 | 3 | 1996 | 5 | 0.100 |
Why?
|
| Chronic Disease | 1 | 2011 | 70 | 0.100 |
Why?
|
| Scopolamine Derivatives | 1 | 1990 | 1 | 0.100 |
Why?
|
| Parasympatholytics | 1 | 1990 | 3 | 0.100 |
Why?
|
| Sleep | 1 | 1990 | 6 | 0.100 |
Why?
|
| Microsomes, Liver | 1 | 1990 | 2 | 0.090 |
Why?
|
| Somatomedins | 1 | 1990 | 4 | 0.090 |
Why?
|
| Coronary Disease | 2 | 2003 | 7 | 0.090 |
Why?
|
| Pituitary Neoplasms | 1 | 1990 | 11 | 0.090 |
Why?
|
| Receptors, Cell Surface | 1 | 1990 | 18 | 0.090 |
Why?
|
| Population Surveillance | 1 | 2010 | 19 | 0.090 |
Why?
|
| Health Surveys | 1 | 2010 | 39 | 0.090 |
Why?
|
| Monitoring, Physiologic | 2 | 1987 | 8 | 0.090 |
Why?
|
| Anxiety | 1 | 2009 | 20 | 0.090 |
Why?
|
| Lung | 1 | 2009 | 12 | 0.090 |
Why?
|
| Sexual Behavior | 1 | 2009 | 32 | 0.090 |
Why?
|
| Insulin-Secreting Cells | 1 | 2009 | 2 | 0.090 |
Why?
|
| Medical Records Systems, Computerized | 1 | 2009 | 11 | 0.090 |
Why?
|
| Cholesterol, HDL | 1 | 2009 | 9 | 0.090 |
Why?
|
| Hypoglycemia | 3 | 1987 | 8 | 0.090 |
Why?
|
| Child | 3 | 2012 | 126 | 0.090 |
Why?
|
| Cross-Sectional Studies | 2 | 2000 | 267 | 0.080 |
Why?
|
| Kinetics | 4 | 2001 | 44 | 0.080 |
Why?
|
| Focus Groups | 2 | 2005 | 23 | 0.080 |
Why?
|
| Guidelines as Topic | 2 | 1998 | 6 | 0.080 |
Why?
|
| Nurses | 1 | 2007 | 3 | 0.080 |
Why?
|
| Patient Selection | 2 | 2009 | 13 | 0.080 |
Why?
|
| ROC Curve | 1 | 2007 | 12 | 0.080 |
Why?
|
| Apoptosis | 1 | 2009 | 162 | 0.080 |
Why?
|
| Weight Gain | 1 | 2006 | 10 | 0.080 |
Why?
|
| Oxidation-Reduction | 3 | 1996 | 12 | 0.070 |
Why?
|
| Angina, Unstable | 1 | 2005 | 1 | 0.070 |
Why?
|
| Arizona | 1 | 2005 | 2 | 0.070 |
Why?
|
| Heart Failure | 1 | 2005 | 4 | 0.070 |
Why?
|
| Continuity of Patient Care | 1 | 2005 | 9 | 0.070 |
Why?
|
| Drug Approval | 1 | 2005 | 1 | 0.070 |
Why?
|
| Marketing | 1 | 2005 | 1 | 0.070 |
Why?
|
| United States Food and Drug Administration | 1 | 2005 | 3 | 0.070 |
Why?
|
| Graves Disease | 1 | 1985 | 2 | 0.070 |
Why?
|
| Glycogen | 6 | 1994 | 9 | 0.070 |
Why?
|
| Urine | 2 | 1983 | 11 | 0.070 |
Why?
|
| Epoxy Compounds | 2 | 1996 | 2 | 0.060 |
Why?
|
| Electrocardiography | 1 | 2004 | 18 | 0.060 |
Why?
|
| Insulin Aspart | 1 | 2004 | 1 | 0.060 |
Why?
|
| Length of Stay | 1 | 2004 | 16 | 0.060 |
Why?
|
| Age of Onset | 1 | 2004 | 4 | 0.060 |
Why?
|
| Single-Blind Method | 1 | 2003 | 5 | 0.060 |
Why?
|
| Diaphragm | 4 | 1978 | 5 | 0.060 |
Why?
|
| Glycosuria | 3 | 1990 | 3 | 0.060 |
Why?
|
| Guideline Adherence | 1 | 2003 | 10 | 0.060 |
Why?
|
| Cell Line | 2 | 1996 | 80 | 0.060 |
Why?
|
| Chromium | 1 | 1983 | 1 | 0.060 |
Why?
|
| Yeast, Dried | 1 | 1983 | 2 | 0.060 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2003 | 1 | 0.060 |
Why?
|
| Educational Status | 1 | 2003 | 24 | 0.060 |
Why?
|
| Communication | 1 | 2003 | 5 | 0.060 |
Why?
|
| Interprofessional Relations | 1 | 2003 | 6 | 0.060 |
Why?
|
| Data Interpretation, Statistical | 1 | 2003 | 6 | 0.060 |
Why?
|
| Urban Population | 1 | 2003 | 57 | 0.060 |
Why?
|
| Diagnosis, Differential | 1 | 2002 | 24 | 0.050 |
Why?
|
| Reimbursement Mechanisms | 1 | 1982 | 1 | 0.050 |
Why?
|
| Risk Assessment | 1 | 2001 | 55 | 0.050 |
Why?
|
| Myocardial Contraction | 1 | 2001 | 2 | 0.050 |
Why?
|
| Dietary Sucrose | 1 | 2001 | 2 | 0.050 |
Why?
|
| Specimen Handling | 1 | 1981 | 4 | 0.050 |
Why?
|
| Calcium | 1 | 2001 | 35 | 0.050 |
Why?
|
| Heart | 1 | 2001 | 15 | 0.050 |
Why?
|
| Medicaid | 1 | 2000 | 7 | 0.050 |
Why?
|
| Homeless Persons | 1 | 2000 | 20 | 0.050 |
Why?
|
| Clinical Trials as Topic | 3 | 1991 | 19 | 0.050 |
Why?
|
| Ketone Bodies | 1 | 1979 | 1 | 0.050 |
Why?
|
| Nicotinic Acids | 1 | 1979 | 1 | 0.050 |
Why?
|
| Natriuresis | 1 | 1979 | 5 | 0.050 |
Why?
|
| Deoxyglucose | 2 | 1996 | 6 | 0.050 |
Why?
|
| Longitudinal Studies | 1 | 1999 | 46 | 0.050 |
Why?
|
| Physician's Role | 1 | 1999 | 3 | 0.040 |
Why?
|
| Medicine | 1 | 1999 | 10 | 0.040 |
Why?
|
| Specialization | 1 | 1999 | 12 | 0.040 |
Why?
|
| False Positive Reactions | 1 | 1999 | 6 | 0.040 |
Why?
|
| Energy Intake | 1 | 1979 | 11 | 0.040 |
Why?
|
| Triiodothyronine | 1 | 1979 | 7 | 0.040 |
Why?
|
| Fructose | 3 | 1979 | 4 | 0.040 |
Why?
|
| National Institutes of Health (U.S.) | 1 | 1998 | 2 | 0.040 |
Why?
|
| Budgets | 1 | 1998 | 2 | 0.040 |
Why?
|
| Controlled Clinical Trials as Topic | 2 | 2008 | 3 | 0.040 |
Why?
|
| Diabetic Foot | 1 | 1998 | 1 | 0.040 |
Why?
|
| Computer Systems | 1 | 1998 | 5 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 1998 | 7 | 0.040 |
Why?
|
| Cost Control | 1 | 1997 | 1 | 0.040 |
Why?
|
| Physicians, Family | 1 | 1997 | 2 | 0.040 |
Why?
|
| Glycerol | 3 | 1975 | 3 | 0.040 |
Why?
|
| Hyperthyroidism | 2 | 1988 | 4 | 0.040 |
Why?
|
| Islets of Langerhans | 2 | 1991 | 5 | 0.040 |
Why?
|
| Cells, Cultured | 2 | 2001 | 164 | 0.040 |
Why?
|
| 3T3 Cells | 1 | 1996 | 16 | 0.040 |
Why?
|
| Plant Gums | 1 | 1996 | 1 | 0.040 |
Why?
|
| Ketones | 1 | 1996 | 1 | 0.040 |
Why?
|
| Polyuria | 1 | 1996 | 1 | 0.040 |
Why?
|
| Urination Disorders | 1 | 1996 | 1 | 0.040 |
Why?
|
| Documentation | 1 | 1996 | 6 | 0.040 |
Why?
|
| Medical Records | 1 | 1996 | 18 | 0.040 |
Why?
|
| Streptozocin | 2 | 1994 | 9 | 0.040 |
Why?
|
| Uremia | 1 | 1976 | 1 | 0.040 |
Why?
|
| Renal Dialysis | 1 | 1976 | 6 | 0.040 |
Why?
|
| Carnitine O-Palmitoyltransferase | 1 | 1996 | 1 | 0.040 |
Why?
|
| Peer Review | 1 | 1975 | 1 | 0.040 |
Why?
|
| Lipodystrophy | 1 | 1975 | 2 | 0.040 |
Why?
|
| Medical Audit | 1 | 1975 | 11 | 0.040 |
Why?
|
| Polycystic Ovary Syndrome | 1 | 1995 | 6 | 0.030 |
Why?
|
| Multicenter Studies as Topic | 1 | 1995 | 3 | 0.030 |
Why?
|
| Nurse Clinicians | 1 | 1995 | 1 | 0.030 |
Why?
|
| 4-Nitrophenylphosphatase | 1 | 1994 | 1 | 0.030 |
Why?
|
| Insulin Antibodies | 2 | 1991 | 2 | 0.030 |
Why?
|
| Mice | 1 | 1996 | 508 | 0.030 |
Why?
|
| Morbidity | 1 | 1994 | 7 | 0.030 |
Why?
|
| Surgical Wound Infection | 1 | 1994 | 2 | 0.030 |
Why?
|
| Diuretics | 1 | 1994 | 4 | 0.030 |
Why?
|
| Phenobarbital | 1 | 1994 | 1 | 0.030 |
Why?
|
| Incidence | 1 | 1994 | 55 | 0.030 |
Why?
|
| Contraceptives, Oral | 1 | 1973 | 1 | 0.030 |
Why?
|
| Drug Administration Routes | 1 | 1993 | 1 | 0.030 |
Why?
|
| Parenteral Nutrition | 1 | 1993 | 2 | 0.030 |
Why?
|
| Gene Expression | 1 | 1993 | 73 | 0.030 |
Why?
|
| Drug Interactions | 1 | 1992 | 18 | 0.030 |
Why?
|
| Consensus Development Conferences as Topic | 1 | 2012 | 1 | 0.030 |
Why?
|
| Freezing | 1 | 1992 | 2 | 0.030 |
Why?
|
| Reserpine | 2 | 1971 | 2 | 0.030 |
Why?
|
| Verapamil | 1 | 1991 | 1 | 0.030 |
Why?
|
| Potassium Channels | 1 | 1991 | 1 | 0.030 |
Why?
|
| Isoquinolines | 1 | 1991 | 2 | 0.030 |
Why?
|
| 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine | 1 | 1991 | 2 | 0.030 |
Why?
|
| Cycloheximide | 1 | 1991 | 4 | 0.030 |
Why?
|
| Tetradecanoylphorbol Acetate | 1 | 1991 | 5 | 0.030 |
Why?
|
| Aminoquinolines | 1 | 1991 | 2 | 0.030 |
Why?
|
| Cattle | 1 | 1991 | 11 | 0.030 |
Why?
|
| Adenosine Triphosphate | 1 | 1991 | 12 | 0.030 |
Why?
|
| Protein Kinase Inhibitors | 1 | 1991 | 12 | 0.030 |
Why?
|
| Pentobarbital | 1 | 1971 | 1 | 0.030 |
Why?
|
| Piperazines | 1 | 1991 | 24 | 0.030 |
Why?
|
| Polysaccharides, Bacterial | 1 | 1971 | 1 | 0.030 |
Why?
|
| Infusions, Parenteral | 4 | 1988 | 7 | 0.030 |
Why?
|
| Stimulation, Chemical | 2 | 1985 | 14 | 0.020 |
Why?
|
| Cacao | 1 | 1990 | 1 | 0.020 |
Why?
|
| Solanum tuberosum | 1 | 1990 | 1 | 0.020 |
Why?
|
| N-Methylscopolamine | 1 | 1990 | 1 | 0.020 |
Why?
|
| Dithiothreitol | 1 | 1990 | 1 | 0.020 |
Why?
|
| Rats, Inbred WF | 1 | 1990 | 1 | 0.020 |
Why?
|
| Receptors, Somatomedin | 1 | 1990 | 1 | 0.020 |
Why?
|
| Molecular Weight | 1 | 1990 | 4 | 0.020 |
Why?
|
| Metabolic Clearance Rate | 2 | 1987 | 2 | 0.020 |
Why?
|
| Intracellular Membranes | 1 | 1990 | 6 | 0.020 |
Why?
|
| Body Water | 2 | 1988 | 5 | 0.020 |
Why?
|
| Statistics as Topic | 1 | 2009 | 11 | 0.020 |
Why?
|
| Biological Clocks | 2 | 1972 | 4 | 0.020 |
Why?
|
| Intracellular Fluid | 1 | 1988 | 2 | 0.020 |
Why?
|
| Starvation | 1 | 1968 | 5 | 0.020 |
Why?
|
| Drug Stability | 1 | 1987 | 1 | 0.020 |
Why?
|
| Species Specificity | 1 | 1987 | 10 | 0.020 |
Why?
|
| Rats, Zucker | 1 | 1987 | 16 | 0.020 |
Why?
|
| Albumins | 1 | 1967 | 2 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 1987 | 17 | 0.020 |
Why?
|
| Tolbutamide | 2 | 1979 | 2 | 0.020 |
Why?
|
| Amyotrophic Lateral Sclerosis | 1 | 1986 | 2 | 0.020 |
Why?
|
| Pancreatic Function Tests | 1 | 1985 | 1 | 0.020 |
Why?
|
| Propranolol | 1 | 1985 | 3 | 0.020 |
Why?
|
| Epinephrine | 1 | 1985 | 7 | 0.020 |
Why?
|
| Isoproterenol | 1 | 1985 | 1 | 0.020 |
Why?
|
| Competency-Based Education | 1 | 2005 | 1 | 0.020 |
Why?
|
| Health Personnel | 1 | 2005 | 13 | 0.020 |
Why?
|
| Community-Institutional Relations | 1 | 2005 | 14 | 0.020 |
Why?
|
| Physical Exertion | 2 | 1976 | 3 | 0.020 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2005 | 64 | 0.020 |
Why?
|
| Diet, Reducing | 3 | 1988 | 3 | 0.020 |
Why?
|
| Thyroxine | 2 | 1985 | 7 | 0.020 |
Why?
|
| In Vitro Techniques | 2 | 1975 | 37 | 0.020 |
Why?
|
| Hair | 1 | 1983 | 2 | 0.010 |
Why?
|
| Glucagon | 1 | 1983 | 4 | 0.010 |
Why?
|
| Erythrocytes | 1 | 1983 | 9 | 0.010 |
Why?
|
| Random Allocation | 1 | 1983 | 15 | 0.010 |
Why?
|
| Lovastatin | 1 | 2003 | 1 | 0.010 |
Why?
|
| Pravastatin | 1 | 2003 | 1 | 0.010 |
Why?
|
| Simvastatin | 1 | 2003 | 1 | 0.010 |
Why?
|
| Fatty Acids, Monounsaturated | 1 | 2003 | 3 | 0.010 |
Why?
|
| Heptanoic Acids | 1 | 2003 | 2 | 0.010 |
Why?
|
| Indoles | 1 | 2003 | 8 | 0.010 |
Why?
|
| Pyrroles | 1 | 2003 | 6 | 0.010 |
Why?
|
| Hydrocortisone | 3 | 1989 | 27 | 0.010 |
Why?
|
| Disease Models, Animal | 2 | 1985 | 143 | 0.010 |
Why?
|
| Injections, Intravenous | 2 | 1974 | 5 | 0.010 |
Why?
|
| Liver Glycogen | 1 | 1982 | 1 | 0.010 |
Why?
|
| Surgical Procedures, Operative | 1 | 1981 | 6 | 0.010 |
Why?
|
| Fura-2 | 1 | 2001 | 1 | 0.010 |
Why?
|
| Starch | 1 | 2001 | 2 | 0.010 |
Why?
|
| Methods | 1 | 1981 | 2 | 0.010 |
Why?
|
| Fluorescent Dyes | 1 | 2001 | 3 | 0.010 |
Why?
|
| Microscopy, Video | 1 | 2001 | 2 | 0.010 |
Why?
|
| Drinking | 1 | 1981 | 8 | 0.010 |
Why?
|
| Calcium Signaling | 1 | 2001 | 5 | 0.010 |
Why?
|
| Heart Ventricles | 1 | 2001 | 12 | 0.010 |
Why?
|
| Rats, Wistar | 1 | 2001 | 35 | 0.010 |
Why?
|
| Myocardium | 1 | 2001 | 15 | 0.010 |
Why?
|
| Eating | 1 | 1981 | 18 | 0.010 |
Why?
|
| Dogs | 2 | 1978 | 5 | 0.010 |
Why?
|
| Circadian Rhythm | 1 | 1979 | 11 | 0.010 |
Why?
|
| Galactose | 1 | 1979 | 1 | 0.010 |
Why?
|
| Triiodothyronine, Reverse | 1 | 1979 | 1 | 0.010 |
Why?
|
| Biological Transport, Active | 1 | 1978 | 3 | 0.010 |
Why?
|
| Lactates | 1 | 1978 | 2 | 0.010 |
Why?
|
| Glycolysis | 1 | 1978 | 4 | 0.010 |
Why?
|
| Transplantation, Homologous | 1 | 1978 | 3 | 0.010 |
Why?
|
| Muscle Development | 1 | 1978 | 22 | 0.010 |
Why?
|
| Kidney Transplantation | 1 | 1978 | 33 | 0.010 |
Why?
|
| Aging | 1 | 1978 | 101 | 0.010 |
Why?
|
| Pregnancy in Diabetics | 2 | 1982 | 4 | 0.010 |
Why?
|
| Models, Biological | 1 | 1996 | 43 | 0.010 |
Why?
|
| Abdomen | 1 | 1975 | 1 | 0.010 |
Why?
|
| Extremities | 1 | 1975 | 1 | 0.010 |
Why?
|
| Genes, Dominant | 1 | 1975 | 1 | 0.010 |
Why?
|
| Kidney Diseases, Cystic | 1 | 1975 | 1 | 0.010 |
Why?
|
| Pedigree | 1 | 1975 | 5 | 0.010 |
Why?
|
| Osteoporosis | 1 | 1975 | 4 | 0.010 |
Why?
|
| Decision Making | 1 | 1975 | 11 | 0.010 |
Why?
|
| Body Composition | 1 | 1975 | 35 | 0.010 |
Why?
|
| Cost Savings | 1 | 1995 | 6 | 0.010 |
Why?
|
| Program Evaluation | 1 | 1995 | 16 | 0.010 |
Why?
|
| Tritium | 1 | 1994 | 2 | 0.010 |
Why?
|
| Lipoprotein Lipase | 1 | 1994 | 3 | 0.010 |
Why?
|
| Arginine | 1 | 1974 | 19 | 0.010 |
Why?
|
| Mydriatics | 1 | 1993 | 3 | 0.010 |
Why?
|
| Photography | 1 | 1993 | 20 | 0.010 |
Why?
|
| Macular Degeneration | 1 | 1993 | 18 | 0.010 |
Why?
|
| Mestranol | 1 | 1973 | 1 | 0.010 |
Why?
|
| Norethindrone | 1 | 1973 | 1 | 0.010 |
Why?
|
| Hypopituitarism | 1 | 1973 | 3 | 0.010 |
Why?
|
| Potassium Chloride | 1 | 1972 | 4 | 0.010 |
Why?
|
| Pancreatectomy | 2 | 1972 | 2 | 0.010 |
Why?
|
| Depression, Chemical | 1 | 1971 | 1 | 0.010 |
Why?
|
| Epididymis | 1 | 1971 | 1 | 0.010 |
Why?
|
| Metabolism | 1 | 1971 | 2 | 0.010 |
Why?
|
| Sodium | 1 | 1971 | 28 | 0.010 |
Why?
|
| Metabolic Diseases | 1 | 1971 | 6 | 0.010 |
Why?
|
| Headache | 1 | 1971 | 1 | 0.010 |
Why?
|
| Pseudomonas | 1 | 1971 | 1 | 0.010 |
Why?
|
| Shivering | 1 | 1971 | 1 | 0.010 |
Why?
|
| Body Temperature | 1 | 1971 | 2 | 0.010 |
Why?
|
| Dialysis | 1 | 1970 | 2 | 0.010 |
Why?
|
| Congenital Abnormalities | 1 | 1970 | 2 | 0.010 |
Why?
|
| Sucrose | 1 | 1990 | 8 | 0.010 |
Why?
|
| Gluconeogenesis | 1 | 1988 | 3 | 0.010 |
Why?
|
| Amino Acids | 1 | 1968 | 16 | 0.010 |
Why?
|
| Sympathetic Nervous System | 1 | 1967 | 1 | 0.000 |
Why?
|
| Plasma Volume | 1 | 1967 | 2 | 0.000 |
Why?
|
| Fatty Acids | 1 | 1967 | 13 | 0.000 |
Why?
|
| Hypoxia | 1 | 1967 | 11 | 0.000 |
Why?
|
| Biological Availability | 1 | 1986 | 3 | 0.000 |
Why?
|
| Macromolecular Substances | 1 | 1986 | 2 | 0.000 |
Why?
|
| Monocytes | 1 | 1986 | 13 | 0.000 |
Why?
|
| Somatostatin | 1 | 1985 | 10 | 0.000 |
Why?
|
| Intraoperative Period | 1 | 1981 | 1 | 0.000 |
Why?
|
| Jejunum | 1 | 1972 | 1 | 0.000 |
Why?
|
| Ileum | 1 | 1972 | 2 | 0.000 |
Why?
|
| Thyroid Hormones | 1 | 1972 | 3 | 0.000 |
Why?
|
| Appetite Regulation | 1 | 1972 | 5 | 0.000 |
Why?
|
| Water-Electrolyte Balance | 1 | 1972 | 13 | 0.000 |
Why?
|
| Feeding Behavior | 1 | 1972 | 26 | 0.000 |
Why?
|
| Hypothalamus | 1 | 1972 | 47 | 0.000 |
Why?
|
| Femoral Vein | 1 | 1972 | 1 | 0.000 |
Why?
|
| Hepatic Veins | 1 | 1972 | 1 | 0.000 |
Why?
|
| Nephrectomy | 1 | 1972 | 1 | 0.000 |
Why?
|
| Potassium | 1 | 1972 | 6 | 0.000 |
Why?
|
| Pancreas | 1 | 1972 | 6 | 0.000 |
Why?
|
| Feedback | 1 | 1972 | 6 | 0.000 |
Why?
|
| Kidney | 1 | 1972 | 36 | 0.000 |
Why?
|
| Autonomic Nerve Block | 1 | 1967 | 2 | 0.000 |
Why?
|
| Central Nervous System | 1 | 1967 | 4 | 0.000 |
Why?
|